Trial Profile
An Open-label, Single-arm, Phase II, Multicenter Study to Evaluate the Efficacy of Nivolumab/Ipilimumab Combination Therapy in Metastatic Melanoma Patients With Symptomatic Brain Metastases
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- 24 Jul 2018 Status changed from recruiting to discontinued.
- 26 Apr 2018 Planned End Date changed from 1 Jan 2018 to 1 Aug 2018.
- 26 Apr 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Aug 2018.